Phanes Therapeutics
- Biotech or pharma, therapeutic R&D
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I/II clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, mavrostobart (PT199), the TWINPEAK study with spevatamig (PT886) and the SKYBRIDGE study with peluntamig (PT217). Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug designations as well as Fast Track designations by the FDA.
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit www.phanesthera.com
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}